id,filing_uuid,filing_type,registrant_name,registrant_id,client_name,filing_year,filing_period,issue_code,specific_issues,government_entities,income_amount,expense_amount,is_no_activity,is_termination,received_date
2458622,6d50b898-5265-4457-9302-c6012138cdb8,2T,"ALLERGAN USA, INC.",63837,"ALLERGAN USA, INC.",2020,second_quarter,PHA,Supporting proposals to strengthen cGMP; encouraging full implementation and enforcement of the Drug Quality and Safety Act.,"Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE,White House Office",,230000,0,1,2020-05-13T14:51:32.380000-04:00
2459820,a68f2658-896e-49e3-817b-5d9f8a42f1e0,2T,"LEBLANC GOVERNMENT RELATIONS, LLC",400670003,"CROSSROADS STRATEGIES ON BEHALF OF ALITHEON, INC.",2020,second_quarter,PHA,In support of Alitheon technology for pharmaceutical verification in difficult locations.,"Defense, Dept of (DOD),Homeland Security, Dept of (DHS),HOUSE OF REPRESENTATIVES,SENATE,Transportation, Dept of (DOT),U.S. Agency for International Development (USAID)",,,0,1,2020-06-03T09:45:04.357000-04:00
2460537,e7adfc09-0a36-4b72-93e6-c1123dd20f30,Q2,JOHNSON MATTHEY INC.,401104441,JOHNSON MATTHEY INC.,2020,second_quarter,PHA,"H.R. 965 and S. 340, CREATES Act of 2019, provisions relating to improving the process by which generic drug manufacturers could obtain sufficient quantities of brand drug samples for testing thereby deterring practices that impede generic entry to the market.

H.R. 938, BLOCKING Act of 2019, provisions relating to discouraging parking of the 180-day exclusivity period for first generic drug manufacturers challenging pharmaceutical patents.

H.R. 3, Lower Drug Costs Now Act of 2019, provisions relating to enhancing first generic drug manufacturers' 180-day exclusivity protections, process improvements and new FDA authority concerning generic drug manufacturers' access to reference samples from branded drug manufacturers, and discouraging parking of the 180-day exclusivity period for first generic drug manufacturers challenging pharmaceutical patents.

H.R. 19, Lower Costs, More Cures Act of 2019, provisions relating to enhancing first generic drug manufacturers' 180-day exclusivity protections, process improvements and new FDA authority concerning generic drug manufacturers' access to reference samples from branded drug manufacturers, and discouraging parking of the 180-day exclusivity period for first generic drug manufacturers challenging pharmaceutical patents.

S. 1895, Lower Health Care Costs Act of 2019, provisions relating to modifications to the exclusivity benefits afforded to first-to-file generic drug manufacturers.","Environmental Protection Agency (EPA),HOUSE OF REPRESENTATIVES",,30000,0,0,2020-07-01T08:10:50.653000-04:00
2460562,5787507a-b41f-45aa-838c-ae6530cb0dfa,2T,HCM STRATEGISTS,400459263,ALLIANCE OF COMMUNITY HEALTH PLANS,2020,second_quarter,PHA,"2593, The Prescription Drug Pricing Reduction Act (PDPRA) of 2019
HR 3, The Elijah E. Cummings Lower Drug Costs Now Act",,,,0,1,2020-07-01T09:39:02.153000-04:00
2460800,30faec26-2935-4cd8-b831-952d72eed84e,Q2,"4C COMMUNICATIONS, INC.",323717,HEALTHCARE LEADERSHIP COUNCIL,2020,second_quarter,PHA,Discussion on pharmaceutical drug pricing; cost of pharmaceutical drugs in the Medicare Part D program,"HOUSE OF REPRESENTATIVES,SENATE",,,0,0,2020-07-02T13:42:46.697000-04:00
2461045,62310649-dcbb-4a28-ab98-bd79e94f9f7f,Q2,THE KUTLER GROUP,401103966,PRIME THERAPEUTICS,2020,second_quarter,PHA,"drug pricing issues
monitor Covid 19 legislation","HOUSE OF REPRESENTATIVES,SENATE",24000,,0,0,2020-07-03T11:31:25.557000-04:00
2461125,34ba2265-c98f-4529-9a5a-13c69dba2614,Q2,RED+BLUE STRATEGIES,400693064,PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION (PCMA),2020,second_quarter,PHA,"H.R. 1425 - The Patient Protection and Affordable Care Enhancement Act - Issues related to policies impacting the price of prescription medications. 

H.R. 6800 - The Heroes Act - Issues related to the role of pharmacy benefits and prescription medications in response to the COVID -19 pandemic.

H.R. 748 - CARES Act -Implementation- Issues related to supporting the national work fighting COVID-19 and ensuring that medication is available during the COVID-19 crisis and beyond.

H.R. 6201 - Families First Coronavirus Response Act - Implementation- Issues related to ensuring that the federal government is best supporting public and private healthcare programs and providers.

H.R. 6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act of 2020 -Implementation- Issues related to supporting programs and institutions supporting during the current pandemic. 

HHS rules and regulations related  to the cost of prescription drugs, including, but not limited to,  limiting rebates in the Medicare and Medicaid prescription drug benefits.","HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2020-07-03T14:03:55.633000-04:00
2461148,dcd15576-6a83-4557-89c8-f2759ab38b59,Q2,RED+BLUE STRATEGIES,400693064,PEW CHARITABLE TRUSTS,2020,second_quarter,PHA,"S. 6725 - The National Defense Authorization Act - Issues related to ensuring that there are antibiotics in the pipeline to ensure that our nation's troops are adequately protected from infection-related complications.

H.R. 6800 - THe HEROES Act - Issues related to continuing the fight against SUD and opioid addiction in the time of COVID.  Issues related to ensuring that there were new, effective antibiotics in the pipeline to treat secondary infections due to hospitalizations for COVID.  Issues related to HIT as a tool during the pandemic. 


H.R. 748 - CARES Act - Implementation - Issues related to supporting the national work fighting COVID-19 and ensuring that antibiotics are available during the COVID-19 crisis and beyond and OTC monograph reform is address to enhance patient safety.

H.R. 6201 - Families First Coronavirus Response Act - Implementation-   Issues related to ensuring that the federal government is best supporting the public good with a focus on ensuring there is a strong antibiotics pipeline to fight secondary infections and over the counter medications are safe and secure.

H.R. 6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act of 2020 -Implementation -  Issues related to supporting programs and institutions supporting during the current pandemic. 

S. 1712/H.R. 4100 - THe DISARM Act - Support for ensuring that there are sufficient antibiotics in the pipeline to meet the national need. 

H.R. 2482 - The Mainstreaming Addiction Treatment Act of 2019 - Support for policies increasing the ability to access MAT to treat addiction. 

Issues related to creating a listing mechanism for dietary supplements. 

Issues related to the implementation on the SUPPORT Act (P.L. 115-271)","HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2020-07-03T14:57:05.807000-04:00
2461156,c785f7de-5fb6-465c-9d6b-bc371e139be7,Q2,RED+BLUE STRATEGIES,400693064,COHERUS BIOSCIENCES,2020,second_quarter,PHA,"Issues focused on Made in America and the importance of keeping Rx-related jobs and manufacturing in the United States. 

H.R. 6800 - The HEROES Act - Issues related to lowering costs of prescription drugs for Americans. 

H.R. 6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act - Implementation- Issues related the COVID-19 that impacts small businesses as well as need for cancer medications for patients.

H.R. 6201 - Families First Coronavirus Response Act  -Implementation -  Issues related to insuring the safety of American families, workers and health providers and the role biosimilars can play. Additionally, policies related to supporting small businesses. 

H.R. 748 - The CARES Act - Implementation-  Issues related to insuring the safety of American families, workers and health providers and the role biosimilars can play. Additionally, policies related to supporting small businesses. 

H.R. 1865 - Further Consolidated Appropriations Act, 2020 - Implementation -  Support for passage of the CREATES Act and other issues that support the country's new biosimilars market place. 

H.R. 3 - Lower Drug Costs Now Act - Issues related to enhancing the development and success of the American biosimilars marketplace.

S. 1895 - The Lowering Health Care Costs Act - provisions related to creating a fair playing field for biosimilars in the United States. 

Issues related to improving and expanding the biosimilars marketplace through policies that will create a more even playing field for biosimilars in the overall prescription drug marketplace in the United States. Areas of focus include policies regarding patent law, public and private reimbursement and FDA interchangeability standards.","Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2020-07-03T15:47:09.990000-04:00
2461407,bf3759e8-2a87-4dc6-91d2-a99e667e0f1d,Q2,ISEMAN & ASSOCIATES LLC,401103582,"TICHENOR VENTURES, LLC",2020,second_quarter,PHA,Monitoring biotech legislation; prescription drug prices,"HOUSE OF REPRESENTATIVES,SENATE",15000,,0,0,2020-07-06T14:03:24.150000-04:00
2461623,370193c2-281b-4443-827d-007bdb2d6238,Q2,AMERICAN COLLEGE OF CLINICAL PHARMACY,57258,AMERICAN COLLEGE OF CLINICAL PHARMACY,2020,second_quarter,PHA,Coverage for direct patient care services of qualified clinical pharmacists under Medicare and other public health programs.,"Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE",,144981,0,0,2020-07-07T04:42:14.807000-04:00
2461663,8c0747c5-2daa-4160-aa22-0d50334767f3,Q2,KEEFE STRATEGIES LLC (FKA KEEFE SINGISER PARTNERS),401105192,CVS HEALTH,2020,second_quarter,PHA,Issues encompassing general education regarding the pharmacy benefit manager/pharmacy industry. Issues related to access and affordability of health care. Issues related to continuation of prescription drug access and testing during COVID crisis.,"HOUSE OF REPRESENTATIVES,SENATE",45000,,0,0,2020-07-07T08:38:32.213000-04:00
2461804,d5656b5c-cf96-4665-9f86-5ef6f35db644,Q2,HOLLAND & KNIGHT LLP,18466,"TEVA PHARMACEUTICALS USA, INC.",2020,second_quarter,PHA,"Drug pricing; Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 (H.R. 6074); Families First Coronavirus Response Act (H.R. 6201); Coronavirus Aid, Relief, and Economic Security (CARES) Act (H.R. 748); Global supply chain issues; National Defense Authorization Act.","HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2020-07-07T13:26:04.840000-04:00
2462244,53f54704-be11-403b-8066-12863b8169a5,Q2,BOYDEN GRAY & ASSOCIATES PLLC,400748240,ILLINOIS CORN GROWERS ASSOCIATION,2020,second_quarter,PHA,Regulation of alcohol for use in hand sanitizer,"Agriculture, Dept of (USDA),Office of Management & Budget (OMB),SENATE",80000,,0,0,2020-07-08T09:35:01.280000-04:00
2462246,e90a1bb7-8808-4976-a9ee-537e1a5381ba,Q2,"PARAGON BIOSCIENCES, LLC",401105338,"PARAGON BIOSCIENCES, LLC",2020,second_quarter,PHA,Issues related to public and private investment in biosciences and R&D,"HOUSE OF REPRESENTATIVES,SENATE",,40000,0,0,2020-07-08T09:38:02.450000-04:00
2462389,36b89b9a-edcd-4c84-8c08-51dbd23a5b61,Q2,THORSEN FRENCH ADVOCACY LLC,400599826,HEALTHCARE DISTRIBUTION ALLIANCE,2020,second_quarter,PHA,"General issues related to prescription drug abuse.
Issues related to pharmaceutical market value. 
Prescription drug importation.
Issues related to regulation of prescription opioid medication.","HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2020-07-08T11:53:36.857000-04:00
2462396,970fce76-6efc-423b-add3-5fc1c27bc125,Q2,THORSEN FRENCH ADVOCACY LLC,400599826,PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA,2020,second_quarter,PHA,"Issues related to pharmaceutical market value.
Global supply chain.
Proposed Notice of Benefit and Payment Parameters (NBPP) Rule for 2021.","HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2020-07-08T11:57:41.750000-04:00
2462426,e85d5b0d-eb02-4971-bca4-fa76088ccbc9,Q2,WAKEFERN FOOD CORP.,400588798,WAKEFERN FOOD CORP.,2020,second_quarter,PHA,"S.988/HR.803 Improving Transparency and Accuracy in Medicare Part D Drug Spending Act, all provisions related to Direct and Indirect Remuneration (DIR) fees.","HOUSE OF REPRESENTATIVES,SENATE",,10000,0,0,2020-07-08T12:39:59.153000-04:00
2462588,73061ec1-61c2-4e04-8dda-32f2807848a6,Q2,PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION,401103605,PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION,2020,second_quarter,PHA,"Discussed role of contract development & manufacturing organizations in COVID-19 therapeutics and vaccines, and potential solutions for drug shortages, including those posed by pandemic sitiuations, in addition to general education about role of bio/pharmaceutical contract manufacturing organizations and development service providers.","HOUSE OF REPRESENTATIVES,SENATE",,50000,0,0,2020-07-08T16:28:15.767000-04:00
2462959,d16ffdc5-c9c5-4148-b3d5-68caf0c4dcad,Q2,"RUBICON ADVISORS, LLC",315091,DYNAVAX TECHNOLOGIES,2020,second_quarter,PHA,"Prescription Drug User Fee, Biomedical Advance Research and Development Authority (BARDA)","HOUSE OF REPRESENTATIVES,SENATE",45000,,0,0,2020-07-09T13:09:52.113000-04:00
2462964,c7a2750e-bc23-4d14-88e8-b6d562e0dac8,Q2,"RUBICON ADVISORS, LLC",315091,"DR. REDDY'S LABORATORIES, LTD",2020,second_quarter,PHA,Prescription Drug User Fee (PDUFA) re authorization.Generic Drug User Fee Act (GDUFA) re authorization. Border Adjustment Tax(BAT)issues,"Drug Enforcement Administration (DEA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE",45000,,0,0,2020-07-09T13:13:57.197000-04:00
2462973,972d6bb1-9b35-4f17-b328-f3d98c20172a,Q2,"RUBICON ADVISORS, LLC",315091,CONSCIOUS DISCIPLINE,2020,second_quarter,PHA,Medicare,"HOUSE OF REPRESENTATIVES,SENATE",37500,,0,0,2020-07-09T13:22:04.457000-04:00
2463006,599b10b9-e8ea-4173-83e0-2ff999ff0a63,Q2,"RUBICON ADVISORS, LLC",315091,"LANNETT COMPANY, INC",2020,second_quarter,PHA,"Medicare and Medicaid, Generic Prescription, COVID-19 Stimulus","Defense, Dept of (DOD),HOUSE OF REPRESENTATIVES,SENATE,Veterans Affairs, Dept of (VA)",60000,,0,0,2020-07-09T13:33:21.667000-04:00
2463030,53e5cd54-a05e-4a99-a4a9-fed934e2b5e9,Q2,"RUBICON ADVISORS, LLC",315091,AVET PHARMACEUTICALS,2020,second_quarter,PHA,"GENERIC DRUG PRICING,HOUSE COMMITTEE ON OVERSIGHT,GOVERNMENT REFORM, FOOD AND DRUG ADMINISTRATION AND COVID-19 DRUG SHORTAGES","Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES",30000,,0,0,2020-07-09T13:54:47.707000-04:00
2463367,fa6dfd70-58b1-4fda-9ae3-31f9a7ea52ea,Q2,AMERICAN PHARMACISTS ASSOCIATION,3071,AMERICAN PHARMACISTS ASSOCIATION,2020,second_quarter,PHA,"H.R. 789 - To amend title XVIII of the Social Security Act to prohibit prescription drug plan sponsors and MA-PD organizations under the Medicare program from retroactively reducing payment on clean claims submitted by pharmacies.
H.R. 803 - This bill prohibits Medicare prescription drug plan sponsors from retroactively reducing payment on clean claims submitted by pharmacies. (A ""clean claim"" is a Medicare claim that is free of defects such as incomplete documentation.)
H.R. 1034 - Phair Pricing Act of 2019; To amend title XVIII of the Social Security Act to require pharmacy-negotiated price concessions to be included in negotiated prices at the point-of-sale under part D of the Medicare program
S. 640 - To amend title XVIII of the Social Security Act to require pharmacy-negotiated price concessions to be included in negotiated prices at the point-of-sale under part D of the Medicare program, and for other purposes.
S. 476 - Creating Transparency to Have Drug Rebates Unlocked (C-Thru) Act of 2019 - To amend titles XI and XVIII of the Social Security Act to provide greater transparency of discounts provided by drug manufacturers.
S. 476 - Creating Transparency to Have Drug Rebates Unlocked (C-Thru) Act of 2019 - To amend titles XI and XVIII of the Social Security Act to provide greater transparency of discounts provided by drug manufacturers.
H.R. 3 Lower Drug Costs Now Act of 2019-To establish a fair price negotiation program, protect the Medicare program from excessive price increases, and establish an out-of-pocket maximum for Medicare part D enrollees, and for other purposes.
S.2543 Prescription Drug Pricing Reduction Act of 2019 -To amend titles XI, XVIII, and XIX of the Social Security Act to lower prescription drug prices in the Medicare and Medicaid programs, to improve transparency related to pharmaceutical prices and transactions, to lower patients' out-of-pocket costs, and to ensure accountability to taxpayers, and for other purposes.
HR 5304 PBM Transparency in Prescription Drug Cost Act - 
To amend title XXVII of the Public Health Service Act to require health plan oversight of pharmacy benefit manager service
HR 5442 - Lowest Price for Patients Act - To amend title XXVII of the Public Health Service Act and title XVIII of the Social Security Act to require pharmacies to disclose any differential between the cost of a prescription drug based on whether certain individuals use prescription drug coverage to acquire such drug, and for other purposes.
S. 3129 - To provide for certain reforms with respect to the Medicare program under title XVIII of the Social Security Act, and for other purposes.
HR 19 - To provide for certain reforms with respect to the Medicare program under title XVIII of the Social Security Act, the Medicaid program under title XIX of such Act, the Food and Drug Administration, and for other purposes. Lower Costs, More Cures Act of 2019.
HR 3 -To establish a fair price negotiation program, protect the Medicare program from excessive price increases, and establish an out-of-pocket maximum for Medicare part D enrollees, and for other purposes.","HOUSE OF REPRESENTATIVES,SENATE",,34000,0,0,2020-07-10T12:21:58.880000-04:00
2463520,b4016690-8adf-47a3-847a-309dae497f03,Q2,PANNONE LOPES DEVEREAUX & O'GARA LLC,401105501,AMGEN,2020,second_quarter,PHA,Prescription drug pricing.,,9000,,0,0,2020-07-10T15:16:24.177000-04:00
2463763,e08a0d9b-0096-4f30-9d8f-f3969077cd59,Q2,"REPUBLIC CONSULTING, LLC",401016871,IQVIA,2020,second_quarter,PHA,Monitor Data and Science Policy.,"Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2020-07-11T12:50:40.997000-04:00
2463945,585fd953-351e-403d-87b3-a02ae9d7a519,Q2,"FLYNN & ASSOCIATES, INC.",15020,PHARMACEUTICAL INDUSTRY LABOR-MANAGEMENT ASSOCIATION,2020,second_quarter,PHA,"ACA Stabilization - Drug Pricing
Drug importation from Canada","HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2020-07-13T09:22:59.507000-04:00
2463991,304cc4d5-0cea-4583-b746-55318673c8a9,Q2,INDEPENDENT PHARMACY COOPERATIVE,313098,INDEPENDENT PHARMACY COOPERATIVE,2020,second_quarter,PHA,"The Prescription Drug Pricing Reduction Act S. 2543-IPC supports.
Improving Transparency and Accuracy in Medicare Part D Spending Act S.988/ HR 803-IPC supports all pharmacy price concessions be reflected at the point-of-sale.
Support regulations that would eliminate pharmacy DIR.
IPC supports Pharmacists as providers under Medicare Part B
IPC supports Pharmacists as Imunnizers
First Families Coronavirus Response Act 2020. IPC supports
The Coronavirus Aid, Relief and Economic Security Act 2020. IPC supports","Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Labor, Dept of (DOL),SENATE",,30000,0,0,2020-07-13T10:40:53.477000-04:00
2464219,92ef6059-076e-42aa-ba9e-4cb26bc5d333,Q2,"BROWN & FORTUNATO, P.C.",401104878,"PROMPTCARE COMPANIES, INC.",2020,second_quarter,PHA,"Issues related to Medicare home infusion therapy benefit and other health care issues.  Issues related to the Medicare DMEPOS competitive bidding program.  Issues related to H.R. 4945 - Safeguarding Medicare Access to Respiratory Therapy Act of 2019; H.R. 1865 - Further Consolidated Appropriations Act, 2020; H.R. 748 - CARES Act; H.R. 6201 - Family First Coronavirus Response Act.  Issues related to H.R. 6218 and S. 3457 - The Preserving Medicare Access to Home Infusion Act.",Centers For Medicare and Medicaid Services (CMS),20000,,0,0,2020-07-13T14:08:05.557000-04:00
2464310,a0179fb6-aad2-40a6-aaf9-dc3c1cabbdbe,Q2,TAUZIN STRATEGIC NETWORKS,400786367,CAPTURERX,2020,second_quarter,PHA,Issues related to the 340b program,"HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2020-07-13T14:58:34.520000-04:00
2464334,6a2e6451-9d09-4cb8-afca-b5da01a0dc23,Q2,POLSINELLI PC,314911,"TEVA PHARMACEUTICALS USA, INC.",2020,second_quarter,PHA,"S. 2543, Prescription Drug Pricing Reduction Act
S. 1895, Lower Health Care Costs Act
H.R. 3, Lower Drug Costs Now Act
Coronavirus stimulus legislation 
Review of Administration drug pricing policies","HOUSE OF REPRESENTATIVES,SENATE",80000,,0,0,2020-07-13T15:13:43.367000-04:00
2464345,ce668b1f-1cef-4b94-ad12-59c7702ab495,Q2,"CRISPR THERAPEUTICS, INC.",401105184,"CRISPR THERAPEUTICS, INC.",2020,second_quarter,PHA,Reimbursement for cell and gene therapies.,"Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE",,80000,0,0,2020-07-13T15:25:46.660000-04:00
2464827,a776c6e3-eebd-4245-8b5d-1091eb11959f,Q2,NATIONAL ASSOCIATION OF CHAIN DRUG STORES,26672,NATIONAL ASSOCIATION OF CHAIN DRUG STORES,2020,second_quarter,PHA,"H.R. 1614 A bill to amend the Controlled Substances Act to establish additional registration requirements for prescribers of opioids, and for other purposes; John S. McCain Opioid Addiction Prevention Act

S. 724 A bill to amend the Controlled Substances Act to establish additional registration requirements for prescribers of opioids, and for other purposes; John S. McCain Opioid Addiction Prevention Act

S.340 CREATES Act of 2019

H.R. 985 FAST Generics Act of 2019

S.640 Phair Pricing Act of 2019

S. 97 Affordable and Safe Prescription Drug Importation Act 

S. 61 Safe and Affordable Drugs from Canada Act of 2019

H.R. 1034 Phair Pricing Act of 2019

H.R. 965 CREATES Act of 2019

H.R. 1478 Affordable Insulin Act of 2019

H.R. 447 Affordable and Safe Prescription Drug Importation Act 

H.R. 1499 Protecting Consumer Access to Generic Drugs Act

H.R. 3417 The Beneficiary Education Tools, Telehealth, and Extenders Re-authorization Act of 2019

H.R. 2296 Fair Accountability and Innovative Research Drug Pricing (FAIR Drug Pricing) Act of 2019

H.R. 1607 Fairness to Pet Owners Act

H.R. 3379 Priced Relief, Innovation, and Competition for Essential Drugs (PRICED) Act

H.R. 478 Safe and Affordable Drugs from Canada Act of 2019

H.R. 3 Lower Drug Costs Now Act of 2019

H.R. 275 Medicare Prescription Drug Price Negotiation Act of 2019

H.R. 448 Medicare Drug Price Negotiation Act

H.R. 1046 Medicare Negotiation and Competitive Licensing Act of 2019

H.R. 5304 PBM Transparency in Prescription Drug Costs Act

H.R. 5172 NOPAIN Act

S. 2543 Prescription Drug Pricing Reduction Act of 2019

S. Rept. 116-120 Prescription Drug Pricing Reduction Act of 2019

S. 2247 Phair Relief Act of 2019

S. 3070 Preventing Pill Mills Through Data Sharing Act

H.R. 3055 Further Continuing Appropriations Act, 2020, and Further Health Extenders Act of 2019

H.R. 19 Lower Costs, More Cures Act on 2019

S. 3129 Lower Costs, More Cures Act on 2019

H.R. 748 Coronavirus Aid, Relief, and Economic Security Act or the CARES Act

H.R. 6573 Help our Heroes Access Medicine Act of 2020

H.R. 6557 MAIL Act

S. 3979 A bill to amend title 10, United States Code, to authorize the Secretary of Defense to temporarily waive cost-sharing amounts under the TRICARE pharmacy benefits program during certain declared emergencies.

H.R.6395 - William M. (Mac) Thornberry National Defense Authorization Act for Fiscal Year 2021","HOUSE OF REPRESENTATIVES,SENATE",,700000,0,0,2020-07-14T10:56:59.123000-04:00
2464856,2d3ce1d7-78ee-4926-a299-44bc0e419ebf,Q2,LUPIN PHARMACEUTICALS INC,401104766,LUPIN PHARMACEUTICALS INC,2020,second_quarter,PHA,Not applicable this quarter.,"HOUSE OF REPRESENTATIVES,SENATE,U.S. Agency for International Development (USAID),U.S. Trade Representative (USTR)",,236935,0,0,2020-07-14T11:24:07.880000-04:00
2464878,218f2d1b-8736-4a99-aac6-4e674989b80f,Q2,CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER,312496,CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER,2020,second_quarter,PHA,"Drug pricing, 340B for children's hospitals","Agency for Healthcare Research & Quality (AHRQ),Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE,White House Office",,40560,0,0,2020-07-14T11:37:14.437000-04:00
2465093,af2398d3-c78c-4211-b8f1-e9d341f40fae,Q2,TODD STRATEGY GROUP,401103321,"ALKERMES, INC.",2020,second_quarter,PHA,Prescription drug pricing.,"HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2020-07-14T13:42:16.427000-04:00
2465138,98c0729c-5668-43ef-a1c1-78522e5f2d6e,Q2,TODD STRATEGY GROUP,401103321,ASTRAZENECA PHARMACEUTICALS LP,2020,second_quarter,PHA,Drug pricing.,"Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2020-07-14T14:06:27.593000-04:00
2465142,2f538d50-a3c7-4bb5-9121-8025ba6cf239,Q2,TODD STRATEGY GROUP,401103321,BAYER CORPORATION,2020,second_quarter,PHA,Drug pricing.,"Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2020-07-14T14:08:29.463000-04:00
2465153,c1a592a0-0e06-4b64-b235-426f0799e858,Q2,TODD STRATEGY GROUP,401103321,BIOTECHNOLOGY INNOVATION ORGANIZATION,2020,second_quarter,PHA,Drug Pricing and Access.,"Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2020-07-14T14:13:32.870000-04:00
2465154,89dfed3b-ca7c-476d-a5f2-0e3e2187fbaa,Q2,TODD STRATEGY GROUP,401103321,"CAREDX, INC.",2020,second_quarter,PHA,Coverage of immunosuppressive drugs.,"Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE",40000,,0,0,2020-07-14T14:14:33.337000-04:00
2465160,fdefb180-2ddb-46d0-9194-44027169ffb3,Q2,TODD STRATEGY GROUP,401103321,EMD SERONO INC.,2020,second_quarter,PHA,Drug pricing policy.,"Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2020-07-14T14:16:36.577000-04:00
2465172,03eb0f84-9f41-409b-b282-96afee9f0446,2T,"MEHLMAN CONSULTING, INC.",284950,FOOD ALLERGY RESEARCH & EDUCATION (FARE),2020,second_quarter,PHA,Labeling of allergens.,"HOUSE OF REPRESENTATIVES,SENATE",10000,,0,1,2020-07-14T14:25:42.157000-04:00
2465224,043333dd-e202-4f1c-b612-3ddf61c0ed12,Q2,TODD STRATEGY GROUP,401103321,"GENENTECH, INC.",2020,second_quarter,PHA,"Prescription drug payment reform.
Supply chain.","Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2020-07-14T14:40:56.667000-04:00
2465271,ac464d07-0c09-407a-8f4e-c30648b56fa5,Q2,TODD STRATEGY GROUP,401103321,"MERCK & CO., INC.",2020,second_quarter,PHA,"Drug Pricing.
S.1712/H.R.4100: DISARM Act of 2019.","HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2020-07-14T14:58:15.973000-04:00
2465290,3643df4f-422a-40b3-99c8-865a8448ff5f,Q2,TODD STRATEGY GROUP,401103321,"NOVARTIS, INC.",2020,second_quarter,PHA,"Drug Pricing.
Supply Chain.","HOUSE OF REPRESENTATIVES,SENATE",20000,,0,0,2020-07-14T15:02:22.297000-04:00
2465299,6d2e4576-9efc-49a8-84a9-00844a9d1502,Q2,TODD STRATEGY GROUP,401103321,PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA,2020,second_quarter,PHA,"Drug Pricing and Access.
Pharmaceutical Supply Chain.","Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2020-07-14T15:04:26.083000-04:00
2465306,4e1c1a70-03c4-446f-b6ef-e12d24d5c23a,Q2,MCDERMOTT+ LLC,401103287,ALLIANCE FOR RURAL HOSPITAL ACCESS,2020,second_quarter,PHA,Amendments to Section 340B of the Public Health Service Act regarding eligibility for rural referral centers and sole community hospitals in the federal discount drug purchasing program.,"Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2020-07-14T15:07:28.920000-04:00
2465313,be7de892-ef9e-4fde-adb6-1044af9142ef,Q2,TODD STRATEGY GROUP,401103321,"US WORLDMEDS, LLC",2020,second_quarter,PHA,Opioid Use Disorder Treatment Policy.,"Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",40000,,0,0,2020-07-14T15:10:32.153000-04:00
2465488,2ee734f1-f16c-41ae-9fb7-1ef4b45cc608,2A,TODD STRATEGY GROUP,401103321,"NOVARTIS, INC.",2020,second_quarter,PHA,"Drug Pricing.
Supply Chain.","HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2020-07-14T16:50:27.757000-04:00
2465494,93bacfe0-5720-47ae-bea9-62f88fc6e25a,2A,TODD STRATEGY GROUP,401103321,"MERCK & CO., INC.",2020,second_quarter,PHA,"Drug Pricing.
S.1712/H.R.4100: DISARM Act of 2019.","HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2020-07-14T16:53:29.587000-04:00
2465850,b43efa7c-6cd5-43a1-b394-cc1ea7e5b51e,Q2,WINNING STRATEGIES WASHINGTON,50796,KALEO,2020,second_quarter,PHA,"Pharmaceutical drug development, including epinephrine for anaphlylaxis; drug access and affordability issues","Federal Aviation Administration (FAA),HOUSE OF REPRESENTATIVES,SENATE",40000,,0,0,2020-07-15T10:48:06.507000-04:00
2466097,8a568a99-8364-4064-9c65-e146a273d44a,Q2,WAXMAN STRATEGIES,401103693,340B HEALTH,2020,second_quarter,PHA,Issues affecting the 340B drug pricing program; Appropriations for 340B program.,"HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2020-07-15T11:43:02.520000-04:00
2466188,3449f9d2-40cf-4aca-bf79-a90f858d0a6a,Q2,GREATER NEW YORK HOSPITAL ASSOCIATION,16830,GREATER NEW YORK HOSPITAL ASSOCIATION,2020,second_quarter,PHA,"Discuss issues related to group purchasing organizations (GPOs) with Congressional staff and members. 
Discuss several pieces of legislation with Congressional staff including: the CREATES Act (H.R. 965/S. 340) (support), the Fast Access for Safe & Timely Generics Act (H.R. 985) (support), the Protecting Consumer Access to Generic Drugs Act (H.R. 1499) (support), the Fair and Immediate Release of Generic Drugs Act (H.R. 1506) (support), the Orange Book Transparency Act (H.R. 1503) (support), the Purple Book Continuity Act (H.R. 1520) (support), and the Bringing Low-Cost Options and Competition While Keeping Incentives for New Generics Act (H.R. 938) (support). 
Discuss the METRIC Act (H.R. 2296) with Congressional staff. 
Discuss legislation to address drug shortages with Congressional staff and members, the MEDS Act (S. 2373) (support), advocate for its inclusion in the CARES Act (H.R. 748).
Discuss the Prescription Drug Pricing Reduction Act of 2019 (S. 2543) with Congressional staff and committee staff.
Discuss Lower Drug Costs Now Act (H.R.3) with Congressional staff.
Discuss drug shortages related to the COVID-19 crisis with Congressional and Administration staff.","Centers For Medicare and Medicaid Services (CMS),Congressional Budget Office (CBO),Defense, Dept of (DOD),Executive Office of the President (EOP),Federal Bureau of Investigation (FBI),Federal Emergency Management Agency (FEMA),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Medicare Payment Advisory Commission (MedPAC),Office of Management & Budget (OMB),President of the U.S.,SENATE,Small Business Administration (SBA),Substance Abuse & Mental Health Services Administration (SAMHSA),White House Office",,570000,0,0,2020-07-15T12:07:24.617000-04:00
2466204,86ed0d0c-6712-4d7e-b188-85eb8f2974b8,2A,TODD STRATEGY GROUP,401103321,"MERCK & CO., INC.",2020,second_quarter,PHA,"Drug Pricing.
S.1712/H.R.4100: DISARM Act of 2019.","HOUSE OF REPRESENTATIVES,SENATE",20000,,0,0,2020-07-15T12:16:26.637000-04:00
2466212,44d0dc66-83d5-4ff3-b36c-bc9609ebb9d1,Q2,CONSUMER HEALTHCARE PRODUCTS ASSOCIATION,29403,CONSUMER HEALTHCARE PRODUCTS ASSOCIATION,2020,second_quarter,PHA,"Pseudoephedrine -- Potential legislation to implement real-time, stop-sale electronic tracking system for sales of medications containing pseudoephedrine in order to preserve consumer access to the ingredient and oppose PSE restrictions such as a prescription requirement (no bill number).

Mandatory recall authority of the FDA

Supporting a process within FDA that ensures clarity and timely outcomes for the FDA, applicants and stakeholders, as well as utilizing existing technologies to further streamline the prescription-to-nonprescription switch application process without changing the existing clear distinction between prescription and nonprescription medicines.

H.R.3164 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2020

S.930 - Allowing Greater Access to Safe and Effective Contraception Act

S.1847/H.R. 3296 - Affordability is Access Act

S.2522 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2020

H.R.6058 - SHOP SAFE Act of 2020

S.3431 - INFORM Consumers Act

Legislation to increase domestic production of pharmaceuticals and the domestic supply chain. 

H.R. 6395 - National Defense Authorization Act for Fiscal Year 2021
S.4049 - National Defense Authorization Act for Fiscal Year 2021","Commerce, Dept of (DOC),Food & Drug Administration (FDA),Homeland Security, Dept of (DHS),HOUSE OF REPRESENTATIVES,SENATE,Treasury, Dept of,Vice President of the U.S.",,128000,0,0,2020-07-15T12:18:27.303000-04:00
2466409,61d5e9f9-4e58-4c87-8307-b3da0acf0ccf,Q2,"MEHLMAN CONSULTING, INC.",284950,THE CAMPAIGN FOR SUSTAINABLE RX PRICING,2020,second_quarter,PHA,"S. 1895 - Lower Health Care Costs Act
S. 2543 - Prescription Drug Pricing Reduction Act of 2019
H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act","Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",110000,,0,0,2020-07-15T13:33:18.350000-04:00
2466899,9b1044e2-1099-488f-9a30-52c831f0a010,Q2,PUBLIC CITIZEN,32362,PUBLIC CITIZEN,2020,second_quarter,PHA,"Access to coronavirus treatments and vaccines, COVID-19 medicine pricing and access, COVID-19 Emergency manufacturing act, transparency for federally support COVID R&D, Pharmaceuticals and antitrust","Consumer Product Safety Commission (CPSC),HOUSE OF REPRESENTATIVES,Securities & Exchange Commission (SEC),SENATE,White House Office",,110000,0,0,2020-07-15T16:15:19.427000-04:00
2467108,e337b789-019f-49f1-bed6-f1949b818dc8,Q2,"MEHLMAN CONSULTING, INC.",284950,BLUE SHIELD OF CALIFORNIA,2020,second_quarter,PHA,"Prescription drug pricing.
H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act","Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2020-07-15T18:13:24.603000-04:00
2467115,175067de-9e50-4fb5-8e80-be44317a7487,Q2,LUNGREN LOPINA LLC,401103314,AMPAC FINE CHEMICALS,2020,second_quarter,PHA,Fair treatment for US based pharmaceutical ingredients,"Drug Enforcement Administration (DEA),HOUSE OF REPRESENTATIVES,SENATE",40000,,0,0,2020-07-15T18:16:26.827000-04:00
2467142,852a4369-0347-47cc-bc7d-56ad78f140e1,Q2,"MEHLMAN CONSULTING, INC.",284950,"AARP, INC.",2020,second_quarter,PHA,"S.1895 - Lower Health Care Costs Act including issues relating to drug pricing 
Older Americans Reauthorization Act
S. 2543 - Prescription Drug Pricing Reduction Act of 2019.
House prescription drug price transparency legislation.","HOUSE OF REPRESENTATIVES,SENATE,Treasury, Dept of",50000,,0,0,2020-07-15T18:54:36.670000-04:00
2467173,a5111f27-5b0a-4a2e-919c-94faefc7e628,Q2,TRINITY HEALTH,24910,TRINITY HEALTH,2020,second_quarter,PHA,S 4160 340B Enable certain hospitals that were participating in or applied for the drug discount program under section 340B of the public health service act prior to the COVID-19 public health emergency to temporarily maintain eligibility for program,"Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",,200000,0,0,2020-07-15T20:03:46.307000-04:00
2467185,41bed9f3-d4dc-4b6e-8c1c-4cffaf72bef4,Q2,"MEHLMAN CONSULTING, INC.",284950,AMERICA'S HEALTH INSURANCE PLANS,2020,second_quarter,PHA,"Prescription drug pricing
H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act","Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE,White House Office",90000,,0,0,2020-07-15T20:06:47.400000-04:00
2467200,d030d77f-55ae-440f-a478-a6a343150d37,Q2,"MEHLMAN CONSULTING, INC.",284950,ASSOCIATION OF ACCESSIBLE MEDICINES,2020,second_quarter,PHA,"Medicaid and Medicare drug pricing.
Prescription drug pricing.
S.1895 - Lower Health Care Costs Act.
H.R. 938 - BLOCKING Act of 2019
H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act
S. 2543 - Prescription Drug Pricing Reduction Act of 2019","Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2020-07-15T20:15:50.177000-04:00
2467342,708d46f0-595d-4194-817c-d3821e3a5c0d,Q2,HOLLAND & KNIGHT LLP,18466,VIATRIS INC,2020,second_quarter,PHA,"Drug shortages, formulary tiering, National Defense Authorization Act (NDAA), biosimilar uptake, the consumer price index, generic drugs.","Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2020-07-16T08:01:29.370000-04:00
2467712,039b73ec-f5e7-443a-ada7-88ee682eb451,Q2,"KOUNTOUPES DENHAM CARR & REID, LLC",320918,ASSOCIATION FOR ACCESSIBLE MEDICINES (FORMERLY - GENERIC PHARMACEUTICAL ASSN),2020,second_quarter,PHA,"Policy matters related to generic pharmaceuticals and biosimilars, including H. R. 985, the FAST Generics Act of 2019. H. R. 1499, the Protecting Consumer Access to Generic Drugs Act of 2019, and H. R. 938, the BLOCKING Act of 2019.  Changes to the Risk Evaluation and Mitigation Strategies (REMS) program.  Reimbursement rate for biosimilars.  S. 1895, the Lower Health Care Costs Act, S.2543, The Prescription Drug Pricing Reduction Act, and H. R. 3,The Lower Drug Costs Now Act. H. R. 1865. Issues related to the implementation of H. R. 748, Coronavirus Aid, Relief, and Economic Security Act (CARES Act), including supply chain issues for generic medicines. Issues related to H.R.6395 and S.4049, National Defense Authorization Act for Fiscal Year 2021, including pharmaceutical supply chain provisions.","Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,Transportation, Dept of (DOT),Vice President of the U.S.",60000,,0,0,2020-07-16T10:43:24.703000-04:00
2467947,1348a79c-aa7b-4bee-9edc-6776bdee273b,Q2,TRAVERE THERAPEUTICS,401104190,TRAVERE THERAPEUTICS,2020,second_quarter,PHA,"H.R. 1781, Payment Commission Data Act; H.R. 1503, Orange Book Transparency Act of 2019; H.R. 1520, Purple Book Continuity Act of 2019; H.R. 965 and S. 340, the CREATES Act; H.R. 2113, STAR Act; S. 474, SPIKE Act/Wyden; S. 1391, FAIR Drug Pricing Act; S. 1895, Lower Health Care Costs Act of 2019; H.R. 2296, FAIR/More  Efficient  Tools  to  Realize  Information  for  Consumers Act; H.R. 987, Strengthening Health Care and Lowering Prescription Drug Costs Act; H.R. 3, Lower Drug Costs Now Act; H.R. 19, Lower Costs More Cures Act and related legislation","Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",,150000,0,0,2020-07-16T11:28:25.487000-04:00
2468086,cc8bd250-45e7-4827-b5e9-16e93ae89954,Q2,"TWENTY-FIRST CENTURY GROUP, INC.",38687,"CARDINAL HEALTH, INC.",2020,second_quarter,PHA,Issues related to the distribution and sale of pharmaceutical and medical products and services; medical and public health preparedness; COVID-19 pandemic response;and the healthcare supply chain.,"HOUSE OF REPRESENTATIVES,SENATE",40000,,0,0,2020-07-16T11:51:04.003000-04:00
2468350,5b550962-4f81-4c53-9ec9-1d8f6a56d127,Q2,SUMMIT PUBLIC AFFAIRS,401105467,VANDA PHARMACEUTICALS INC.,2020,second_quarter,PHA,"Issues affecting the pharmaceutical industry, including the prescription drug approval process, animal testing, and gastroparesis issues.
Administration of the 21st Century Cares Act (Pub. L. No. 114-255).
Administration of the Coronavirus Aid, Relief, and Economic Security (CARES) Act (Pub. L. No. 116-136).
COVID-19 Clinical Trials.
Agriculture, Rural Development, FDA, and Related Agencies Appropriations for FY2021, provisions regarding FDA testing for new drug applications.","HOUSE OF REPRESENTATIVES,SENATE",40000,,0,0,2020-07-16T12:41:24.497000-04:00
2468585,7d989835-62aa-4d8a-bf8f-84be3cfaaa5a,Q2,"KOUNTOUPES DENHAM CARR & REID, LLC",320918,"GLENMARK PHARMACEUTICALS, INC., USA",2020,second_quarter,PHA,"General information about the company and the industry.  Issues related to affordability and pricing of pharmaceuticals.  Issues related to the implementation of H.R. 748, Coronavirus Aid, Relief, and Economic Security Act (CARES Act), including drug supply chain dynamics.  H.R. 6800, the HEROES Act. 
Issues related to the federal response to the COVID-19 pandemic.","Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2020-07-16T13:19:31.067000-04:00
2468663,c7bfa499-17d8-4956-8e92-c76780639b35,Q2,ATRIUM HEALTH-FORMERLY KNOWN AS CAROLINAS HEALTHCARE SYSTEM,58534,ATRIUM HEALTH - FORMERLY KNOWN AS CAROLINAS HEALTHCARE SYSTEM,2020,second_quarter,PHA,"Opposition to any provision in any bill to reduce the scope and use of the 340B Drug Discount benefit; 

HR 4710 340B PAUSE Act Any provision(s) reducing or changing the 340B Drug Discount Program or benefits to hospitals limiting hospital access to the benefit and or improving or updating the program's guidelines.

H.R. 3. Lower Prescription Drug Costs Now Act - legislation that would make a series of changes to the Medicare program in an effort to lower the price of prescription drugs.","Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",,5987,0,0,2020-07-16T13:37:53.657000-04:00
2468854,78f5e830-9a3d-4c31-be85-3b3371bf219b,Q2,"KOUNTOUPES DENHAM CARR & REID, LLC",320918,BLOOD CANCER UNITED (FORMERLY REPORTED ASTHE LEUKEMIA AND LYMPHOMA SOCIETY),2020,second_quarter,PHA,Issues related to the cost of care and protecting patient access to blood cancer treatment.  Issues related to specialty drug tiers.,"Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2020-07-16T14:19:54.790000-04:00
2469290,903c4911-dfa2-45da-8cb4-5e6ea1e11711,Q2,"TARPLIN, DOWNS & YOUNG, LLC",304736,ASTRAZENECA,2020,second_quarter,PHA,"Drug coverage & reimbursement

no specific bills, Import Safety, drug development policy, drug shortages, supply chain integrity, Innovation, reimportation, transparency, 340B, pay for delay

H.R. 3 - Lower Drug Costs Now Act
S. 2543 - Prescription Drug Pricing Reduction Act
S. 1895 - Lower Health Care Costs Act
S. 3013 - Encouraging Innovative Benefit Design to Lower Costs for Seniors Act
S. 3129 - Lower Costs, More Cures Act of 2019","Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2020-07-16T15:33:59.117000-04:00
2469329,d95d9aaa-b269-4f6a-b359-3f5b63aa3139,Q2,BURRELL INTERNATIONAL GROUP LLC,401103483,ACER THERAPEUTICS,2020,second_quarter,PHA,"No specific legislative vehicles.  Issues are, generally, orphan drug legislation, rare disease legislation, drug pricing policy","HOUSE OF REPRESENTATIVES,SENATE",10000,,0,0,2020-07-16T15:42:11.010000-04:00
2469332,6074ba7b-2153-42b8-9219-7f5c35b3cc67,Q2,340B HEALTH,316434,340B HEALTH,2020,second_quarter,PHA,"The 340B Drug Pricing Program; FY 2021 L-HHS Appropriations; H.R. 3, Lower Drug Costs Now Act of 2019; S. 2543, Prescription Drug Pricing Reduction Act (PDPRA) of 2019; H.R. 5281, Drug Price Transparency in Medicaid Act of 2019; H.R.6074, Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; H.R.6201, Families First Coronavirus Response Act; H.R.748, CARES Act; HR 19, Lower Costs, More Cures Act of 2019","Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE",,273761,0,0,2020-07-16T15:42:12.893000-04:00
2469347,e1cc85e2-986f-47a0-824d-b1f7ac0d6080,Q2,CAPITOL COUNSEL LLC,313715,VERTEX PHARMACEUTICALS INCORPORATED,2020,second_quarter,PHA,Monitoring and advocacy on matters related to the pharmaceutical industry.,"HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2020-07-16T15:44:18.950000-04:00
2469491,51d966c5-aefa-4769-aad1-e1f595df9924,Q2,"TARPLIN, DOWNS & YOUNG, LLC",304736,HEALTHCARE DISTRIBUTION ALLIANCE (HEALTHCARE DISTRIBUTION MANAGMENT ASSN.),2020,second_quarter,PHA,"Importation of prescription drugs (H.R. 447, H.R. 478, H.R. 1478, S. 61, S. 97, S. 658, S. 844)
Opioid Abuse - General issues related to opioid drug abuse (Implementation of Public Law 115-271)
Implementation of Public Law 113-54 (DSCSA)
Issues Related to ARCOS data and suspicious order record requirements & reporting
Block, Report, and Suspend Suspicious Shipments Act of 2019 (H.R. 3878)","Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",80000,,0,0,2020-07-16T16:09:59.097000-04:00
2469546,b7daf880-bcf4-42b0-b420-31a8d2d6e3cf,Q2,BLUECROSS BLUESHIELD OF TENNESSEE,6440,BLUECROSS BLUESHIELD OF TENNESSEE,2020,second_quarter,PHA,"Opioid and prescription drug pricing issues; Rx drug rebates; regulation of pharmacy benefit managers; CREATES Act;.

H.R.3 - 116th Congress (2019-2020)
Lower Drug Costs Now Act of 2019","HOUSE OF REPRESENTATIVES,SENATE",,25000,0,0,2020-07-16T16:19:12.743000-04:00
2470411,cf5b2a53-dc52-4c1b-9105-538c7f7841bc,Q2,HEALTHCARE DISTRIBUTION ALLIANCE(HDA)(FORMERLY HEALTHCARE DISTRIBUTION MANAGEMENT ASSOCIATION (HDMA),28776,HEALTHCARE DISTRIBUTION ALLIANCE (FORMERLY - HDMA),2020,second_quarter,PHA,"Opioid Abuse - General issues related to opioid abuse (implementation of Public Law 115-271)
Issues related to ARCOS data and suspicious order record requirements and reporting 
Importation of Prescription Drugs (HR 447, HR 478, HR 1478, S 61, S 97, S 658, S 844, Public Law 108-173) 
Implementation of Public Law 113-54 (DSCSA) 
Block, Report, And Suspend Suspicious Shipments Act of 2019 (HR 3878)","Drug Enforcement Administration (DEA),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",,334536,0,0,2020-07-17T08:55:45.857000-04:00
2470504,1d148a5e-a5a5-4994-beb1-d957624506c3,Q2,FAEGRE DRINKER BIDDLE & REATH LLP,12631,ALLIANCE FOR SAFE ONLINE PHARMACIES (ASOP GLOBAL),2020,second_quarter,PHA,Illicit prescription drug sales online; rouge internet drug sellers; dangers of counterfeit medicines; risks of drug importation on patient safety; domain name system accountability regarding COVID-19 frauds; WHOIS,"Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE",70000,,0,0,2020-07-17T09:20:08.173000-04:00
2470520,ed995da5-1e49-430b-8de7-d15e1397135d,Q2,FAEGRE DRINKER BIDDLE & REATH LLP,12631,NATIONAL ASSOCIATION OF BOARDS OF PHARMACY,2020,second_quarter,PHA,"Medication safety, pharmacy regulation, and the opioid epidemic; Prescription drug monitoring programs; COVID-19 response","Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE",110000,,0,0,2020-07-17T09:25:12.707000-04:00
2470641,13c3ddb2-8dc3-46c5-a7ec-68814f318b0f,Q2,MR. VINCENT A. PANVINI,401008845,PHRMA,2020,second_quarter,PHA,"Position on Price Controls; patent Protections, Importation of Biopharmaceuticals.","HOUSE OF REPRESENTATIVES,SENATE",,,0,0,2020-07-17T09:57:38.823000-04:00
2470790,525d8eae-7551-4d9d-a14b-0eae5ad905da,Q2,MCGUIREWOODS CONSULTING (A SUBSIDIARY OF MCGUIREWOODS LLP),24486,AMAZON.COM,2020,second_quarter,PHA,Drug pricing & transparency,"Federal Aviation Administration (FAA),HOUSE OF REPRESENTATIVES,SENATE,Transportation, Dept of (DOT)",60000,,0,0,2020-07-17T10:26:15.187000-04:00
2470934,e6951ffd-d508-4153-b022-8afb63f21c31,Q2,VAN SCOYOC ASSOCIATES,39837,ZEBRA TECHNOLOGIES CORP.,2020,second_quarter,PHA,"Public Law 113-54, Drug Quality and Security Act, Drug labeling implementation 

Temperature monitoring technology for COVID-19 vaccines",HOUSE OF REPRESENTATIVES,30000,,0,0,2020-07-17T10:45:41.817000-04:00
2470982,53638916-aa3f-4a4c-9416-a79542824cf2,Q2,"TARPLIN, DOWNS & YOUNG, LLC",304736,BIOTECHNOLOGY INDUSTRY ORGANIZATION,2020,second_quarter,PHA,"H.R. 1781 - Payment Commission Data Act of 2019
H.R. 938 - the BLOCKING Act of 2019
H.R. 1520 - the Purple Book Continuity Act of 2019
H.R. 1503 - the Orange Book Transparency Act of 2019
H.R. 1499 - Protecting Consumer Access to Generic Drugs Act of 2019
H.R. 965 - the CREATES Act of 2019
S. 1895 - Lower Health Care Costs Act
S. 1416 - Affordable Prescriptions For Patients Act of 2019 
H.R. 3 - Lower Drug Costs Now Act
S. 2543 - Prescription Drug Pricing Reduction Act
S. 3013 - Encouraging Innovative Benefit Design to Lower Costs for Seniors Act
S. 3129 - Lower Costs, More Cures Act of 2019


no specific bills, Drug Safety, Prescription Drug Importation, Import Safety, supply chain integrity, biosimilars, patent settlements, break through therapies, Innovation, transparency","Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE",80000,,0,0,2020-07-17T10:58:55.060000-04:00
2470995,0d467441-7536-4e71-80d8-d73ae1ab4b10,2A,FAEGRE DRINKER BIDDLE & REATH LLP,12631,NATIONAL ASSOCIATION OF BOARDS OF PHARMACY,2020,second_quarter,PHA,"Medication safety, pharmacy regulation, and the opioid epidemic; Prescription drug monitoring programs; COVID-19 response","Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE",,,0,0,2020-07-17T11:01:58.223000-04:00
2471012,fbad7239-e33e-41a4-b0f4-bd3414d5d732,Q2,"BLUE CROSS AND BLUE SHIELD OF FLORIDA, INC.",6382,BLUE CROSS AND BLUE SHIELD OF FLORIDA INC,2020,second_quarter,PHA,"Opioids; CREATES Act; Drug Pricing

HR 4712 (116th Congress), Fairness in Orphan Drug Exclusivity Act, by Rep. Madeleine Dean (D-PA). Amend the Federal Food, Drug, and Cosmetic Act with respect to limitations on exclusive approval or licensure of orphan drugs.

HR 5578 (116th Congress), Recall Unsafe Drugs Act of 2020, by Rep. Rosa DeLauro (D-CT). Provide for the mandatory recall of drugs regulated by the Food and Drug Administration.

HR 5663 (116th Congress), Safeguarding Therapeutics Act, by Rep. Brett Guthrie (R-KY). Give authority to the Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, to destroy counterfeit devices.

HR 5691 (116th Congress), Insulin Affordability Data Collection Act, by Rep. Angie Craig (D-MN). Require the Secretary to conduct a study and issue a report on the affordability of insulin.

HR 5749 (116th Congress), Affordable Insulin for All Act, by Rep. Charlie Crist (D-FL). Establish the American Insulin Program to provide for lower prices for insulin drugs, to maintain effort throughout the insulin supply chain.

HR 5894 (116th Congress), Transparency in Prescription Drug Advertising Act, by Rep. Sharice Davids (D-KS). Directs the Secretary of Health and Human Services to issue guidance requiring the list prices of drugs to be included in advertisements for such drugs.

HR 5927 (116th Congress), Safe Medicine Act, by Rep. Bill Posey (R-FL). Directs the Secretary of Health and Human Services to study American dependence on unsafe Chinese pharmaceuticals and to empower the Food and Drug Administration to mandate drug recalls in the case of critical contamination.

HR 5982 (116th Congress), Safe Medicine Act, by Rep. Bill Posey (R-FL). Directs the Secretary of Health and Human Services to study American dependence on Chinese pharmaceuticals and to empower the Food and Drug Administration to issue boxed warnings in the case of critical contamination.

HR 6193 (116th Congress), Medication Access in Emergencies Act of 2020, by Rep. Chris Pappas (D-NH). Require group health plans and health insurance issuers offering group or individual health insurance coverage to provide benefits under such plan or such coverage for a 30-day refill of prescription drugs to individuals who reside in emergency areas during emergency periods.

HR 6731 (116th Congress), Securing Americas Pharmaceutical Supply Chain Act, by Rep. Pete Stauber (R-MN). Require executive agencies to purchase pharmaceuticals from the United States.","Centers For Medicare and Medicaid Services (CMS),Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Labor, Dept of (DOL),Office of Management & Budget (OMB),SENATE,White House Office",,350000,0,0,2020-07-17T11:08:04.047000-04:00
2471162,87cc0a13-3144-467f-9bc6-9aa6978ab981,Q2,"OLSSON, FRANK, WEEDA, TERMAN & MATZ, PC",30212,NATIONAL ASSOCIATION OF CHAIN DRUG STORES,2020,second_quarter,PHA,"Drug pricing, Direct and Indirect remuneration fees, Medicare, COVID-19","Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office",50000,,0,0,2020-07-17T11:29:40.020000-04:00
2471397,1b59552e-253f-4791-b4c5-4997b870c586,Q2,CENTER FOR INDIVIDUAL FREEDOM,63952,CENTER FOR INDIVIDUAL FREEDOM,2020,second_quarter,PHA,"Buy American Pharmaceutical Mandate  

Correspondence with White House, United States Senate and United States House of Representatives in opposition to any legislation or executive order imposing Buy American mandates upon pharmaceutical production or procurement; research relating thereto.","Centers For Medicare and Medicaid Services (CMS),Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,Treasury, Dept of,White House Office",,10000,0,0,2020-07-17T12:04:45.667000-04:00
2471435,c393b01b-01b8-4aac-b7e8-70bf9a997b25,Q2,UNIVERSITY OF IOWA,49191,UNIVERSITY OF IOWA,2020,second_quarter,PHA,N/A,"Defense, Dept of (DOD),HOUSE OF REPRESENTATIVES,Natl Oceanic & Atmospheric Administration (NOAA),SENATE",,70000,0,0,2020-07-17T12:07:48.827000-04:00
2471494,fd7268f0-0989-42ab-93b8-f73ccd64b51e,Q2,ACG ADVOCACY,2057,WALGREEN CO.,2020,second_quarter,PHA,"Drug Pricing Policy Issues.
Data privacy and DIR fee reform.
Public Health Crisis.
H.R.748/S.3548: Coronavirus Aid, Relief, and Economic Security Act or the CARES Act.","Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office",50000,,0,0,2020-07-17T12:13:02.557000-04:00
2471605,b2b63435-485b-4330-8f6b-83ab581ec6e4,Q2,ACG ADVOCACY,2057,GENENTECH INC,2020,second_quarter,PHA,"Drug Pricing Issues.
Public Health Crisis.
H.R.748/S.3548: Coronavirus Aid, Relief, and Economic Security Act or the CARES Act.","Commerce, Dept of (DOC),HOUSE OF REPRESENTATIVES,SENATE,White House Office",40000,,0,0,2020-07-17T12:27:37.973000-04:00
2471694,1dd43867-19bf-491f-8e32-f2bdd6d5d93b,Q2,MCDERMOTT+ LLC,401103287,CAMPAIGN FOR SUSTAINABLE DRUG PRICING,2020,second_quarter,PHA,"S. 1895 - Lower Health Care Costs Act
S. 2543 - Prescription Drug Pricing Reduction Act of 2019
H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act","Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2020-07-17T12:34:01.690000-04:00
2472366,9d7a16b8-d63a-4300-8539-8167875bfded,Q2,"TARPLIN, DOWNS & YOUNG, LLC",304736,NOVO NORDISK INC.,2020,second_quarter,PHA,"H.R. 1520 Purple Book Continuity Act of 2019; H.R. 1503 Orange Book Transparency Act of 2019; issues related to importation; issues related to 340B; H.R. 4244 MAGIC (Market Access for Generic Insulin Competition) Act to provide for a pathway for chemically synthesized insulin to be approved under an abbreviated new drug application submitted under the Federal Food, Drug, and Cosmetic Act)","Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Natl Economic Council (NEC),SENATE",60000,,0,0,2020-07-17T13:58:59.297000-04:00
2472653,5552821e-1ea2-44ea-892f-6702e326aa00,Q2,KING & SPALDING LLP,21632,"SUMITOMO PHARMA AMERICA (FORMERLY SUNOVION PHARMACEUTICALS, INC.)",2020,second_quarter,PHA,Issues related to drug pricing and six protected classes,HOUSE OF REPRESENTATIVES,60000,,0,0,2020-07-17T14:33:08.243000-04:00
2472883,84b0cd60-36cc-47c6-bbb6-637bec61e2bd,Q2,"BANNER PUBLIC AFFAIRS, LLC",401046942,THE CIGNA GROUP AND SUBSIDIARIES (FKA CIGNA CORPORATION AND SUBSIDIARIES),2020,second_quarter,PHA,Prescription drug pricing.,"HOUSE OF REPRESENTATIVES,SENATE",20000,,0,0,2020-07-17T14:54:07.613000-04:00
2473003,0dbc8786-099d-4ff8-8e6c-9cb045a9c069,Q2,"GOVERNMENT COUNSEL, LLC",401105070,HEALTHCARE DISTRIBUTION ALLIANCE,2020,second_quarter,PHA,"Issues related to ARCOS data and suspicious order record requirements and reporting (S.3070-Preventing Pill Mills Through Data Sharing Act, S. 2686 & H.R. 4814-Suspicious Order Identification Act of 2019, H.R. 3878-Block, Report And Suspend Suspicious Shipments Act of 2020);implementation of Public Law 113-54 (DSCSA).","HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2020-07-17T15:03:34.997000-04:00
2473522,4f33e2ee-684e-45a0-946f-b3c3fde16ea0,Q2,E3 STRATEGIC CONSULTING GROUP,401104104,HEINZ STRATEGIES LLC (ON BEHALF OF PILMA),2020,second_quarter,PHA,"Prescription drug industry issues relating to domestic construction and maintenance employment and all other issues affecting employment in the industry, generally; H.R.1425 - Patient Protection and Affordable Care Enhancement Act","HOUSE OF REPRESENTATIVES,SENATE",20000,,0,0,2020-07-17T15:42:54.223000-04:00
2473527,f8421604-c57a-49cb-b7ab-7a1316d58b95,Q2,E3 STRATEGIC CONSULTING GROUP,401104104,PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION,2020,second_quarter,PHA,"Prescription drug industry issues relating to domestic construction and maintenance employment and all other issues affecting employment in the industry, generally; H.R.1425 - Patient Protection and Affordable Care Enhancement Act","HOUSE OF REPRESENTATIVES,SENATE",20000,,0,0,2020-07-17T15:43:57.160000-04:00
2474049,0d055890-7798-4ef6-bdaa-c2367bd44819,Q2,"AMERICAN FEDERATION OF STATE, COUNTY AND MUNICIPAL EMPLOYEES",2321,AMERICAN FEDERATION OF STATE COUNTY AND MUNICIPAL EMPLOYEES,2020,second_quarter,PHA,HR 1425- The Patient Protection and Health Care Enhancement Act,"HOUSE OF REPRESENTATIVES,SENATE",,660000,0,0,2020-07-17T16:30:06.220000-04:00